New sensitive tools for hepatitis B virus (HBV) detection in liver transplantation: What will be their impact on the prophylaxis of HBV infection?

Liver Transplantation

Volumn 13, Issue 8, 2007, Pages 1084-1087

  Samuel, Didier ^a,c   Roque Afonso, Anne Marie ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ASPARTIC ACID; CIRCULAR DNA; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; METHIONINE; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; TYROSINE; VIRUS DNA;

ANTIBIOTIC RESISTANCE; DNA DETERMINATION; DRUG POTENTIATION; EDITORIAL; GENE LOCUS; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REINFECTION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; VIRUS CELL INTERACTION; VIRUS DETECTION; VIRUS LOAD;

EID: 34548148919     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21156     Document Type: Editorial

References (22)

1. Samuel D, Forns X, Berenguer M, Trantwein C, Burroughs A, Rizzetto M, Trepo C. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006;45: 127-143,
2. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993,329:1842-1847.
3. Shouval D, Samuel D. Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 2000;32:1189-1195.
4. Roche B, Feray C, Gigou M, Roque-Afonso AM, Arulnaden JL, Delvart V, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003;38:86-95.
5. Terrrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 2005;11: 716-732,
6. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology 2001;33:424-432.
7. Neff GW, O'Brien CB, Nery J, Shire N, Montalbano M, Ruiz P, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004;10:1372-1378.
8. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28:585-589.
9. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002;35:1528-1535.
10. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:903-910.
11. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004;10:968-974.
12. Tuttleman J, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 1986;47:451-460.
13. Newbold J, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995;69:3350-3357.
14. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126: 1750-1758.
15. Marzano A, Gaia S, Ghisetti V, Carensi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005;11:402-409.
16. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS, NIH HBV-OLT study group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Liver Transpl 2007;13:1137-1144.
17. Feray C, Zignego AL, Samuel D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplant model. Transplantation 1990; 49:1155-1158.
18. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-188.
19. Roque Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002;50:95-99.
20. Dickson R, Everhart J, Lake JR, Wei Y, Seaberg E, Wiesner R, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997;113:1168-1174.
21. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005;42:302-308.
22. Samuel D. Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there. J Hepatol 2001;34:943-945.